Why Tigecycline Resistance Is a Concern
Tigecycline, a glycylcycline antibiotic used for multidrug-resistant infections like complicated skin infections and intra-abdominal infections, faces growing resistance, mainly from Acinetobacter baumannii, Klebsiella pneumoniae, and Enterobacterales. Resistance often arises via efflux pumps, ribosomal protection, or mutations, amplified by overuse in hospitals. Limiting it requires targeted infection control to curb spread and selective pressure.
Core Infection Control Measures for Hospitals
Implement antibiotic stewardship programs (ASP) first: restrict tigecycline to confirmed susceptible infections via susceptibility testing, use narrow-spectrum alternatives when possible, and monitor usage with de-escalation protocols. The CDC and WHO recommend ASPs reduce resistance by 20-30% in similar scenarios [1][2].
Combine with standard precautions:
- Hand hygiene with alcohol-based rubs before/after patient contact (compliance >70% cuts transmission).
- Contact precautions for colonized/resistant cases: single rooms, gowns/gloves, dedicated equipment.
- Environmental cleaning with disinfectants effective against Gram-negatives (e.g., bleach or hydrogen peroxide-based).
Screen high-risk patients (e.g., ICU admits from endemic areas) for tigecycline-resistant organisms via rectal/axillary swabs.
How Surveillance Fits In
Routine active surveillance detects outbreaks early: weekly point-prevalence screening in ICUs, with molecular typing (e.g., PFGE or WGS) to track clones. Report to local health authorities; the EU's EARS-Net shows surveillance halves outbreak duration [3]. Track tigecycline MICs in hospital labs to flag rising resistance trends.
Device and Procedure-Specific Steps
For tigecycline's common settings:
- Catheter care: Chlorhexidine bundles reduce line-associated infections by 50%, limiting tigecycline need [4].
- Ventilator hygiene: Oral chlorhexidine rinses and subglottic suctioning prevent VAP from resistant pathogens.
- Surgical prophylaxis: Single-dose alternatives to tigecycline unless essential.
Evidence from Outbreak Control
In a 2019 A. baumannii outbreak, combining cohorting, enhanced cleaning, and tigecycline moratorium eliminated transmission in 4 weeks [5]. Similar successes in China with CRKP involved closing wards temporarily and switching to colistin [6]. No unique tigecycline-specific measures exist beyond these; they mirror carbapenemase control.
Challenges and When Measures Fail
Resistance persists in high-prevalence areas (e.g., >50% in some Asian ICUs) despite controls, due to community reservoirs or travel. Measure failure signals need for cohorting or negative-pressure rooms. Patient isolation duration: until 2-3 negative cultures.
Alternatives if Resistance Emerges Locally
Shift to eravacycline or omadacycline (newer glycylcyclines with better potency) under stewardship, or combinations like tigecycline + colistin for salvage [7].
[1]: CDC, Core Elements of Hospital Antibiotic Stewardship Programs (cdc.gov/antibiotic-use/hcp/implementation-core-elements.html)
[2]: WHO, GLASS Report 2022 (who.int/publications/i/item/9789240062702)
[3]: ECDC, Surveillance of Antimicrobial Resistance in Europe 2022 (ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2022-2020-data)
[4]: Pronovost et al., NEJM 2006 (nejm.org/doi/full/10.1056/NEJMoa052092)
[5]: Durante-Mangoni et al., Clin Infect Dis 2019 (academic.oup.com/cid/article/69/12/2123/5488705)
[6]: Zhong et al., Antimicrob Resist Infect Control 2021 (aricjournal.biomedcentral.com/articles/10.1186/s13756-021-00929-0)
[7]: USCAST, Tigecycline Use Guidance (uscast.org/tigecycline.html)